In a precautionary statement about two reports published in the Annals of Internal Medicine, the American Association of Clinical Endocrinologists warned that "misinterpretation ... may cause patients to discontinue needed treatment for diabetes."
In a precautionary statement about two reports published in the Annals of Internal Medicine, the American Association of Clinical Endocrinologists warned that "misinterpretation ... may cause patients to discontinue needed treatment for diabetes."
The two case reports each concern a patient who developed liver dysfunction after recently starting treatment with rosiglitazone (Avandia,® manufactured by SmithKline Beecham) to improve the control of diabetes. The patients recovered after discontinuation of rosiglitazone and showed improvement in their other medical conditions.
The Annals of Internal Medicine authors suggest the liver dysfunction was due to hepatotoxicity related to the use of rosiglitazone, but an AACE spokesperson stated that there might be alternative explanations for the findings. The guidelines for liver function testing for all patients receiving this thiazolodenedione or "glitazone" class of medications remain prudent, as the FDA-approved package inserts suggest.
"These reports must be taken in the context of the risk/benefit profile of the glitazones," said Daniel Einhorn, MD, AACE board of directors member. The class includes rosiglitazone, troglitazone (Parke-Davis' Rezulin®) and pioglitazone (Eli Lilly's and Takeda's Actos®). PR
FDA Approves Roche’s Alecensa as Adjuvant Treatment for ALK-Positive Early-Stage NSCLC
April 19th 2024Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.